You are currently browsing the archives for 29 January 2017.
Displaying 1 entry.

The Phase Ia single-center trial evaluating the safety erectalis for Sale.

The Phase Ia single-center trial evaluating the safety, tolerability, pharmacokinetic profile and evaluate pharmacological activity of CR845 in a double-blind, randomized, placebo – controlled, single escalating intravenous dose study in 54 healthy male and female volunteers. CR845 was shown that at all doses studied sure erectalis for Sale . No reports of serious side effects or adverse central nervous system activity Preclinical , the observed increases in systemic exposure to CR845. Low doses of CR845 consequence plasma levels at or above the plasma levels of drug associated with the likely clinical analgesic efficacy.

The company plans its intravenous formulation of CR845 into Phase II trials later move forward in 2008. Based on the demonstrated safety, tolerability and bioactivity of of this formulation in Phase I, Cara will continue to develop its oral formulation of CR845 for advancement into Phase I.